论文部分内容阅读
目的:探讨腹腔置管持续引流联合白蛋白治疗顽固性腹水疗效。方法:选取收治的肝硬化顽固性腹水患者60例,随机分为观察组与对照组,观察组进行中心静脉置管套件行腹腔置管进行持续性腹水引流,对照组则进行常规方法行腹腔穿刺+腹水引流术,同时2组患者均给予联合白蛋白基础治疗,观察2组患者的肝肾功能,对比2组患者治疗的有效率、白蛋白的使用情况、并发症情况、住院天数及住院费用等指标。结果:2组患者治疗后情况有所好转。观察组的总有效率86.7%,对照组的总有效率为46.7%,同时肝肾功能得到明显改善,具有明显差异P<0.05。在患者住院期间观察组的并发症情况、白蛋白用量、住院时间、住院费用要明显低于对照组,2组差异明显,P<0.05。结论:与传统行腹腔穿刺+腹水引流术相比,腹腔置管持续引流联合白蛋白治疗顽固腹水的临床效果更明显,能够有效的提高患者的治愈率,在并发症的发病率,住院时间、住院费用具有明显优势,值得在临床推广。
Objective: To investigate the effect of continuous peritoneal drainage combined with albumin in treatment of refractory ascites. Methods: Sixty patients with cirrhosis and refractory ascites were randomly divided into observation group and control group. The observation group received continuous ascites drainage through the central venous catheterization kit and the control group underwent routine abdominal paracentesis + Ascites drainage, while the two groups were given combined albumin basic treatment, liver and kidney function was observed in two groups of patients, the effective rate of treatment compared to two groups, the use of albumin, complications, hospitalization days and hospitalization costs And other indicators. Results: After treatment, the two groups improved. The total effective rate of the observation group was 86.7%, while that of the control group was 46.7%. Meanwhile, the liver and kidney functions were significantly improved with a significant difference of P <0.05. During the hospitalization of patients during the observation group complications, the amount of albumin, hospital stay, hospitalization costs were significantly lower than the control group, significant difference between the two groups, P <0.05. Conclusion: Compared with traditional peritoneal puncture and ascites drainage, the clinical effect of continuous peritoneal drainage combined with albumin in the treatment of stubborn ascites is more obvious, which can effectively improve the cure rate of patients, the incidence of complications, length of stay, Hospitalization costs have obvious advantages, it is worth in the clinical promotion.